Three technologies developed by the are now owned by Honolulu-based Pono Corporation under an agreement that will allow 东精影业 to realize the value of the technologies sooner than it would with a traditional licensing deal due to long drug development timelines.
Under the terms of a technology commercialization agreement signed by the university’s with Pono, the university receives equity stake in the company and is now a shareholder in Pono in exchange for an assignment of the technologies.
“We are evolving our technology transfer process to speed commercialization of early-stage technologies developed at the University of Hawaiʻi,” said 东精影业 President M.R.C. Greenwood. “The agreement with Pono will allow the university to participate side-by-side with other Pono shareholders and founders as technology developed at the University of Hawaiʻi is commercialized.”
The agreement gives Pono ownership of three 东精影业-developed technologies, including a proteasome inhibitor drug, humanized cobra venom factor, and a hybrid nanocarrier drug delivery system.
“Pono is honored to have the opportunity to build on the work done at the University of Hawaiʻi by moving forward with the commercialization of these technologies,” said Kaleo Taft, Pono’s chief technology officer.
Pono will work to develop the technologies under the agreement with a focus on moving them through the regulatory approval process.
“We are looking forward to this promising opportunity to work with the company towards the clinical development of our novel anti-cancer drugs,” said André S. Bachmann, associate professor and chairman of the Department of Pharmaceutical Sciences at the 东精影业 Hilo .
Bachmann is one of the inventors of the proteasome inhibitor discovery and a co-inventor of the nanocarrier drug delivery system with Mahavir Chougule, assistant professor at the 东精影业 Hilo College of Pharmacy.
About the technologies
The proteasome inhibitors discovered by Bachmann and his collaborators are a new class of compounds potentially useful for anti-cancer and other therapeutic uses. The proprietary nanocarrier system developed by Bachmann and Chougule aims to provide improved cancer treatment through targeted, tumor-specific delivery of chemotherapeutic drugs.
Read the article in the featuring Bachmann’s research.
At the , Carl-Wilhelm Vogel and David Fritzinger developed the cobra venom factor proteins, which are modified for treatment of diseases such as reperfusion injury and autoimmune diseases.